Toshiyuki Minami
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Toshiyuki Minami has a total of 178 co-authors. Here are the top co-authors by number of shared publications:
- Takashi Kijima
Division of Respiratory Medicine, Department of Internal Medicine, Hyogo Medical University, Nishinomiya 663-8501, Japan
13 shared publications - Kozo Kuribayashi
Department of Respiratory Medicine and Hematology, Hyogo Medical University, Nishinomiya, Japan
7 shared publications - Izumi Nagatomo
Health and Counseling Center, Osaka University, Toyonaka, Japan
6 shared publications Osamu Morimura
6 shared publications- Atsushi Kumanogoh
Department of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, The University of Osaka, Suita, Japan
5 shared publications Hirotoshi Ishigaki
Department of Respiratory Medicine, Hyogo Prefectural Kakogawa Medical Center, Japan; Division of Respiratory Medicine, Department of Internal Medicine, Hyogo College of Medicine, Japan
4 shared publications
Latest Publications
- Open Access
- 17 November 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (11) , 1831
Antitumor Effects of a Small Artificial RNA Sequence in Malignant Pleural Mesothelioma Through Suppression of Cell Cycle-Related Transcriptional Programs
Background/Objectives: Malignant pleural mesothelioma (MPM) is an aggressive malignancy with a poor prognosis and limited therapeutic options. Small RNA-based therapeutics may provide a means of simultaneously modulating multiple oncogenic pathways. We screened candidate small RNAs for antitumor activity in MPM and investigated the molecular basis of the response to the selected sequence. We aimed to identify a small RNA with reproducible antitumor activity in human mesothelioma cells and to define the signaling and transcriptional programs associated with its activity. Methods: Candidate small RNAs were transfected into three human mesothelioma cell lines (H2052, H2452, and H28). Cell viability and proliferation were assessed by WST-8 and BrdU incorporation assays. Intracellular signaling was examined using dual-luciferase reporters, and RNA sequencing with gene set enrichment analysis (GSEA) was used to characterize transcriptional changes. Results: Among the tested RNAs, the small artificial sequence (SAS) most consistently reduced cell viability and significantly suppressed proliferation in all three cell lines. Untreated mesothelioma cells showed prominent enrichment of E2F Targets compared with normal lung tissue, whereas SAS treatment suppressed E2F-associated cell-cycle programs and significantly reduced BrdU incorporation, consistent with inhibition of G1/S cell-cycle progression. SAS also reduced AP1 and SRE activities in H2452 cells but not in H2052 cells, indicating cell line-dependent modulation of MAPK-related signaling. SAS also induced interferon- and inflammatory response gene sets, with particularly strong cytokine induction observed after phosphorothioate (PS) modification of the passenger strand. Conclusions: SAS exerted reproducible antitumor effects in human mesothelioma cells, with suppression of cell proliferation and E2F-associated cell-cycle programs as the most consistent findings. These results support further investigation of SAS in MPM, although its therapeutic efficacy remains to be established in vivo.
- 17 November 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (11) , 1831
Open AccessAntitumor Effects of a Small Artificial RNA Sequence in Malignant Pleural Mesothelioma Through Suppression of Cell Cycle-Related Transcriptional Programs
Background/Objectives: Malignant pleural mesothelioma (MPM) is an aggressive malignancy with a poor prognosis and limited therapeutic options. Small RNA-based therapeutics may provide a means of simultaneously modulating multiple oncogenic pathways. We screened candidate small RNAs for antitumor activity in MPM and investigated the molecular basis of the response to the selected sequence. We aimed to identify a small RNA with reproducible antitumor activity in human mesothelioma cells and to define the signaling and transcriptional programs associated with its activity. Methods: Candidate small RNAs were transfected into three human mesothelioma cell lines (H2052, H2452, and H28). Cell viability and proliferation were assessed by WST-8 and BrdU incorporation assays. Intracellular signaling was examined using dual-luciferase reporters, and RNA sequencing with gene set enrichment analysis (GSEA) was used to characterize transcriptional changes. Results: Among the tested RNAs, the small artificial sequence (SAS) most consistently reduced cell viability and significantly suppressed proliferation in all three cell lines. Untreated mesothelioma cells showed prominent enrichment of E2F Targets compared with normal lung tissue, whereas SAS treatment suppressed E2F-associated cell-cycle programs and significantly reduced BrdU incorporation, consistent with inhibition of G1/S cell-cycle progression. SAS also reduced AP1 and SRE activities in H2452 cells but not in H2052 cells, indicating cell line-dependent modulation of MAPK-related signaling. SAS also induced interferon- and inflammatory response gene sets, with particularly strong cytokine induction observed after phosphorothioate (PS) modification of the passenger strand. Conclusions: SAS exerted reproducible antitumor effects in human mesothelioma cells, with suppression of cell proliferation and E2F-associated cell-cycle programs as the most consistent findings. These results support further investigation of SAS in MPM, although its therapeutic efficacy remains to be established in vivo.
- Open Access
- 6 July 2026
- Published by JMIR Publications Inc. in JMIR Cancer
- Vol. 12, e97890
Real-World Impact of Electronic Patient-Reported Outcomes on Early Intervention Among Older Patients With Lung Cancer: Prospective Cohort Study
Background: Electronic patient-reported outcomes (ePROs) have demonstrated greater sensitivity in detecting adverse events than clinician-reported outcomes. However, conventional care faces challenges related to recall bias, and evidence from real-world populations of older adults is limited. This study evaluates the feasibility of an ePRO system integrated with ecological momentary assessment and ecological momentary intervention (EMI) to facilitate a concordance model within the framework of digital transformation in health care. Objective: This study aimed to evaluate the satisfaction, usability, and clinical impact of an ePRO system integrated with ecological momentary assessment and EMI in a real-world cohort of older patients with lung cancer and to investigate its ability to facilitate a patient-centered concordance model within the framework of digital transformation in health care. Methods: In this single-center prospective cohort study, 35 patients with lung cancer used the Welby My Carte ONC app to record daily symptoms and visual data. Satisfaction and usability were evaluated using 10-point scales at the end of the first and third treatment cycles. The study focused on the clinical impact of EMI triggered by ePRO data, such as early detection of toxicity. Results: The cohort included a high proportion of older patients (20/35, 57%) aged 70 to 89 years. Satisfaction and usability scores significantly improved over time (satisfaction: 6.0 to 8.0, P <.001; usability: 5.0 to 8.0, P <.001). ePRO monitoring enabled the early detection of critical events, including immune-related uveitis (case 1), Stevens-Johnson syndrome (case 2), rare drug-induced purpura (case 3), and the monitoring of infusion-related reactions (case 4). Conclusions: ePRO monitoring is feasible for older patients with lung cancer and enhances safety through timely EMI. It serves as a core component of a comprehensive patient support program and supports the transition to a more active concordance model, ultimately improving patient well-being.
- 6 July 2026
- Published by JMIR Publications Inc. in JMIR Cancer
- Vol. 12, e97890
Open AccessReal-World Impact of Electronic Patient-Reported Outcomes on Early Intervention Among Older Patients With Lung Cancer: Prospective Cohort Study
Background: Electronic patient-reported outcomes (ePROs) have demonstrated greater sensitivity in detecting adverse events than clinician-reported outcomes. However, conventional care faces challenges related to recall bias, and evidence from real-world populations of older adults is limited. This study evaluates the feasibility of an ePRO system integrated with ecological momentary assessment and ecological momentary intervention (EMI) to facilitate a concordance model within the framework of digital transformation in health care. Objective: This study aimed to evaluate the satisfaction, usability, and clinical impact of an ePRO system integrated with ecological momentary assessment and EMI in a real-world cohort of older patients with lung cancer and to investigate its ability to facilitate a patient-centered concordance model within the framework of digital transformation in health care. Methods: In this single-center prospective cohort study, 35 patients with lung cancer used the Welby My Carte ONC app to record daily symptoms and visual data. Satisfaction and usability were evaluated using 10-point scales at the end of the first and third treatment cycles. The study focused on the clinical impact of EMI triggered by ePRO data, such as early detection of toxicity. Results: The cohort included a high proportion of older patients (20/35, 57%) aged 70 to 89 years. Satisfaction and usability scores significantly improved over time (satisfaction: 6.0 to 8.0, P <.001; usability: 5.0 to 8.0, P <.001). ePRO monitoring enabled the early detection of critical events, including immune-related uveitis (case 1), Stevens-Johnson syndrome (case 2), rare drug-induced purpura (case 3), and the monitoring of infusion-related reactions (case 4). Conclusions: ePRO monitoring is feasible for older patients with lung cancer and enhances safety through timely EMI. It serves as a core component of a comprehensive patient support program and supports the transition to a more active concordance model, ultimately improving patient well-being.
- Open Access
- 21 June 2026
- Published by Elsevier in European Journal of Cancer
- Vol. 244
Impact of preexisting interstitial lung disease on pneumonitis and survival during first-line immune checkpoint inhibitor-based therapy in non-small cell lung cancer
- 21 June 2026
- Published by Elsevier in European Journal of Cancer
- Vol. 244
Open AccessImpact of preexisting interstitial lung disease on pneumonitis and survival during first-line immune checkpoint inhibitor-based therapy in non-small cell lung cancer
- Open Access
- 12 April 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Real-world impact of electronic patient-reported outcomes on early intervention in elderly patients with lung cancer: a prospective cohort study (Preprint)
BACKGROUND Electronic patient-reported outcomes (ePRO) have demonstrated higher sensitivity in detecting adverse events than clinician-reported outcomes. However, conventional care faces challenges with recall bias, and evidence in real-world elderly populations is limited. This study evaluates the feasibility of an ePRO system integrated with Ecological Momentary Assessment (EMA) and Intervention (EMI) to facilitate a concordance model within the framework of Digital Transformation (DX) in healthcare. OBJECTIVE This study aims to evaluate the satisfaction, usability, and clinical impact of an ePRO system integrated with Ecological Momentary Assessment (EMA) and Intervention (EMI) in a real-world cohort of elderly lung cancer patients, investigating its ability to facilitate a patient-centered concordance model within the framework of Digital Transformation (DX) in healthcare. METHODS In this single-center prospective cohort study, 35 lung cancer patients used the "Welby My Carte ONC" application to record daily symptoms and visual data. Satisfaction and usability were evaluated using 1–10 scales at the end of the first and third treatment cycles. The study focused on the clinical impact of EMI triggered by ePRO data, such as early detection of toxicities. RESULTS The cohort included a high proportion of elderly patients (n=20 in their 70s and 80s). Satisfaction and usability scores significantly improved over time (Satisfaction: 6.0 to 8.0; Usability: 5.0 to 8.0). ePRO enabled early detection of critical events, including immune-related uveitis (Case 1), Stevens–Johnson syndrome (Case 2), rare drug-induced purpura (Case 3), and facilitated monitoring of infusion-related reactions (Case 4). CONCLUSIONS ePRO is feasible for elderly lung cancer patients and enhances safety through timely EMI. It serves as a core component of a comprehensive Patient Support Program (PSP) and supports the transition to an active concordance model, ultimately improving patient well-being.
- 12 April 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessReal-world impact of electronic patient-reported outcomes on early intervention in elderly patients with lung cancer: a prospective cohort study (Preprint)
BACKGROUND Electronic patient-reported outcomes (ePRO) have demonstrated higher sensitivity in detecting adverse events than clinician-reported outcomes. However, conventional care faces challenges with recall bias, and evidence in real-world elderly populations is limited. This study evaluates the feasibility of an ePRO system integrated with Ecological Momentary Assessment (EMA) and Intervention (EMI) to facilitate a concordance model within the framework of Digital Transformation (DX) in healthcare. OBJECTIVE This study aims to evaluate the satisfaction, usability, and clinical impact of an ePRO system integrated with Ecological Momentary Assessment (EMA) and Intervention (EMI) in a real-world cohort of elderly lung cancer patients, investigating its ability to facilitate a patient-centered concordance model within the framework of Digital Transformation (DX) in healthcare. METHODS In this single-center prospective cohort study, 35 lung cancer patients used the "Welby My Carte ONC" application to record daily symptoms and visual data. Satisfaction and usability were evaluated using 1–10 scales at the end of the first and third treatment cycles. The study focused on the clinical impact of EMI triggered by ePRO data, such as early detection of toxicities. RESULTS The cohort included a high proportion of elderly patients (n=20 in their 70s and 80s). Satisfaction and usability scores significantly improved over time (Satisfaction: 6.0 to 8.0; Usability: 5.0 to 8.0). ePRO enabled early detection of critical events, including immune-related uveitis (Case 1), Stevens–Johnson syndrome (Case 2), rare drug-induced purpura (Case 3), and facilitated monitoring of infusion-related reactions (Case 4). CONCLUSIONS ePRO is feasible for elderly lung cancer patients and enhances safety through timely EMI. It serves as a core component of a comprehensive Patient Support Program (PSP) and supports the transition to an active concordance model, ultimately improving patient well-being.
- Open Access
- 19 February 2026
- Published by Elsevier in Lung Cancer
- Vol. 214, 109336
Comparison of long-term survival between nivolumab plus ipilimumab with chemotherapy and pembrolizumab with chemotherapy in advanced non-small cell lung cancer: A multicenter retrospective cohort study
- 19 February 2026
- Published by Elsevier in Lung Cancer
- Vol. 214, 109336
Open AccessComparison of long-term survival between nivolumab plus ipilimumab with chemotherapy and pembrolizumab with chemotherapy in advanced non-small cell lung cancer: A multicenter retrospective cohort study
- Open Access
- 30 January 2026
- Published by Wiley in Cancer Science
- Vol. 117 (4) , 929-942
Impact of Sequential Ramucirumab Plus Docetaxel After PD ‐1 Inhibitors on Anti‐ PD ‐1 Antibody‐Bound T‐Cell Dynamics and Clinical Outcomes
Ramucirumab plus docetaxel (RAM+DOC) demonstrates clinical activity after programmed cell death‐1 (PD‐1) inhibitors in advanced non‐small cell lung cancer (NSCLC); however, the underlying mechanisms remain unclear. We aimed to evaluate clinical efficacy and explore immunologic dynamics and benefit‐associated biomarkers. Patients treated with RAM+DOC after PD‐1 inhibitors were enrolled in a multicenter prospective cohort. Anti‐PD‐1 antibody bound (IgG4 + ) T‐cell subsets were measured at baseline (T0) and after 2–3 cycles (T1), reflecting residual anti‐PD‐1 antibody binding on circulating T cells. T1/T0 ratios of immune subsets were calculated to assess dynamics. Landmark analyses at T1 evaluated associations with progression‐free survival (PFS) and overall survival (OS). Prognostic biomarkers were assessed at baseline. Among 27 evaluable patients, the objective response rate was 37.0%, median PFS 5.1 months, and OS 10.4 months. RAM + DOC responders had higher IgG4 + CD8 + T‐cell and lower IgG4 + Treg T1/T0 ratios (both p < 0.001). Higher IgG4 + CD8 + ratios were associated with longer landmark PFS ( p = 0.002) and OS ( p = 0.016) and were inversely correlated with IgG4 + Treg ratios ( p = 0.008). Among the baseline factors, high IgG4 + CD8 + Temra conferred survival benefits (OS, not reached vs. 8.2 months; p = 0.006), and low vascular endothelial growth factor (VEGF)‐C levels were associated with longer OS (not reached vs. 8.5 months, p = 0.044). Both variables remained independent prognostic factors of PFS and OS in multivariable analysis. Our findings suggest that sequential strategy administering RAM+DOC during persistent binding of anti–PD‐1 antibody to T cells may be beneficial. IgG4 + CD8 + Temra and VEGF‐C levels at RAM+DOC initiation may serve as biomarkers of survival benefit. Trial Registration: UMIN‐Clinical Trials Registry (UMIN000050478)
- 30 January 2026
- Published by Wiley in Cancer Science
- Vol. 117 (4) , 929-942
Open AccessImpact of Sequential Ramucirumab Plus Docetaxel After PD ‐1 Inhibitors on Anti‐ PD ‐1 Antibody‐Bound T‐Cell Dynamics and Clinical Outcomes
Ramucirumab plus docetaxel (RAM+DOC) demonstrates clinical activity after programmed cell death‐1 (PD‐1) inhibitors in advanced non‐small cell lung cancer (NSCLC); however, the underlying mechanisms remain unclear. We aimed to evaluate clinical efficacy and explore immunologic dynamics and benefit‐associated biomarkers. Patients treated with RAM+DOC after PD‐1 inhibitors were enrolled in a multicenter prospective cohort. Anti‐PD‐1 antibody bound (IgG4 + ) T‐cell subsets were measured at baseline (T0) and after 2–3 cycles (T1), reflecting residual anti‐PD‐1 antibody binding on circulating T cells. T1/T0 ratios of immune subsets were calculated to assess dynamics. Landmark analyses at T1 evaluated associations with progression‐free survival (PFS) and overall survival (OS). Prognostic biomarkers were assessed at baseline. Among 27 evaluable patients, the objective response rate was 37.0%, median PFS 5.1 months, and OS 10.4 months. RAM + DOC responders had higher IgG4 + CD8 + T‐cell and lower IgG4 + Treg T1/T0 ratios (both p < 0.001). Higher IgG4 + CD8 + ratios were associated with longer landmark PFS ( p = 0.002) and OS ( p = 0.016) and were inversely correlated with IgG4 + Treg ratios ( p = 0.008). Among the baseline factors, high IgG4 + CD8 + Temra conferred survival benefits (OS, not reached vs. 8.2 months; p = 0.006), and low vascular endothelial growth factor (VEGF)‐C levels were associated with longer OS (not reached vs. 8.5 months, p = 0.044). Both variables remained independent prognostic factors of PFS and OS in multivariable analysis. Our findings suggest that sequential strategy administering RAM+DOC during persistent binding of anti–PD‐1 antibody to T cells may be beneficial. IgG4 + CD8 + Temra and VEGF‐C levels at RAM+DOC initiation may serve as biomarkers of survival benefit. Trial Registration: UMIN‐Clinical Trials Registry (UMIN000050478)
- Open Access
Radiofrequency Ablation for Recurrent Pleural Mesothelioma
Background/Objectives: Pleural mesothelioma (PM) frequently recurs despite multimodal therapy. Here, we aimed to retrospectively evaluate the safety and potential clinical benefit of radiofrequency ablation (RFA) for recurrent PM. Methods: Fourteen consecutive patients underwent CT-guided RFA between July 2019 and June 2025. The cohort comprised 13 men and 1 woman, with a median age of 69 (range, 54–77) years. All patients had previously received systemic therapy, and 12 had undergone surgery. Seven patients (50%) presented with multiple lesions, and 25 tumors (median diameter 1.8 cm; range, 0.5–7.0 cm) were treated in 23 sessions. Outcomes assessed were local tumor control, complications, and survival. Local progression and overall survival were estimated using Kaplan–Meier analysis. Adverse events were classified according to the Society of Interventional Radiology guidelines. Results: Technical success was achieved in all sessions. Two tumors showed local recurrence, corresponding to 1- and 2-year local progression rates of 10.6%. Seven patients showed distant metastases, most of whom subsequently received systemic therapy. Three patients died, two from disease progression and one from treatment-related gastrointestinal perforation during therapy for an unrelated cancer. The overall survival rates were 100%, 100%, and 60% at 1, 3, and 5 years, respectively. Major and minor complications occurred in one case each (4.3%): a refractory skin ulcer and retroperitoneal hematoma, respectively. Conclusions: RFA was technically feasible and generally well tolerated and helped achieve encouraging local control and survival in patients with recurrent PM, warranting further evaluation of RFA as a complementary approach in multimodal treatment strategies.
Open AccessRadiofrequency Ablation for Recurrent Pleural Mesothelioma
Background/Objectives: Pleural mesothelioma (PM) frequently recurs despite multimodal therapy. Here, we aimed to retrospectively evaluate the safety and potential clinical benefit of radiofrequency ablation (RFA) for recurrent PM. Methods: Fourteen consecutive patients underwent CT-guided RFA between July 2019 and June 2025. The cohort comprised 13 men and 1 woman, with a median age of 69 (range, 54–77) years. All patients had previously received systemic therapy, and 12 had undergone surgery. Seven patients (50%) presented with multiple lesions, and 25 tumors (median diameter 1.8 cm; range, 0.5–7.0 cm) were treated in 23 sessions. Outcomes assessed were local tumor control, complications, and survival. Local progression and overall survival were estimated using Kaplan–Meier analysis. Adverse events were classified according to the Society of Interventional Radiology guidelines. Results: Technical success was achieved in all sessions. Two tumors showed local recurrence, corresponding to 1- and 2-year local progression rates of 10.6%. Seven patients showed distant metastases, most of whom subsequently received systemic therapy. Three patients died, two from disease progression and one from treatment-related gastrointestinal perforation during therapy for an unrelated cancer. The overall survival rates were 100%, 100%, and 60% at 1, 3, and 5 years, respectively. Major and minor complications occurred in one case each (4.3%): a refractory skin ulcer and retroperitoneal hematoma, respectively. Conclusions: RFA was technically feasible and generally well tolerated and helped achieve encouraging local control and survival in patients with recurrent PM, warranting further evaluation of RFA as a complementary approach in multimodal treatment strategies.
- Open Access
- 8 December 2025
- Published by MDPI AG in Preprints.org
Radiofrequency Ablation for Recurrent Pleural Mesothelioma
Background/Objectives: Pleural mesothelioma (PM) frequently recurs despite multimodal therapy. Here, we aimed to retrospectively evaluate the safety and potential clinical benefit of radiofrequency ablation (RFA) for recurrent PM. Methods: Fourteen consecutive patients underwent CT-guided RFA between July 2019 and June 2025. The cohort comprised 13 men and 1 woman, with a median age of 69 (range, 54–77) years. All patients had previously received systemic therapy and 12 had undergone surgery. Seven patients (50%) presented with multiple lesions, and 25 tumors (median diameter 1.8 cm; range, 0.5–7.0 cm) were treated in 23 sessions. Outcomes assessed were local tumor control, complications, and survival. Local progression and overall survival were estimated using Kaplan–Meier analysis. Adverse events were classified according to the Society of Interventional Radiology guidelines. Results: Technical success was achieved in all sessions. Two tumors showed local recurrence, corresponding to 1- and 2-year local progression rates of 10.6%. Seven patients showed distant metastases, most of whom subsequently received systemic therapy. Three patients died, two from disease progression and one from treatment-related gastrointestinal perforation during therapy for an unrelated cancer. The overall survival rates were 100%, 100%, and 60% at 1, 3, and 5 years, respectively. Major and minor complications occurred in one case each (4.3%): a refractory skin ulcer and retroperitoneal hematoma, respectively. Conclusions: RFA was technically feasible and generally well tolerated, and helped achieve encouraging local control and survival in patients with recurrent PM, warranting further evaluation of RFA as a complementary approach in multimodal treatment strategies.
- 8 December 2025
- Published by MDPI AG in Preprints.org
Open AccessRadiofrequency Ablation for Recurrent Pleural Mesothelioma
Background/Objectives: Pleural mesothelioma (PM) frequently recurs despite multimodal therapy. Here, we aimed to retrospectively evaluate the safety and potential clinical benefit of radiofrequency ablation (RFA) for recurrent PM. Methods: Fourteen consecutive patients underwent CT-guided RFA between July 2019 and June 2025. The cohort comprised 13 men and 1 woman, with a median age of 69 (range, 54–77) years. All patients had previously received systemic therapy and 12 had undergone surgery. Seven patients (50%) presented with multiple lesions, and 25 tumors (median diameter 1.8 cm; range, 0.5–7.0 cm) were treated in 23 sessions. Outcomes assessed were local tumor control, complications, and survival. Local progression and overall survival were estimated using Kaplan–Meier analysis. Adverse events were classified according to the Society of Interventional Radiology guidelines. Results: Technical success was achieved in all sessions. Two tumors showed local recurrence, corresponding to 1- and 2-year local progression rates of 10.6%. Seven patients showed distant metastases, most of whom subsequently received systemic therapy. Three patients died, two from disease progression and one from treatment-related gastrointestinal perforation during therapy for an unrelated cancer. The overall survival rates were 100%, 100%, and 60% at 1, 3, and 5 years, respectively. Major and minor complications occurred in one case each (4.3%): a refractory skin ulcer and retroperitoneal hematoma, respectively. Conclusions: RFA was technically feasible and generally well tolerated, and helped achieve encouraging local control and survival in patients with recurrent PM, warranting further evaluation of RFA as a complementary approach in multimodal treatment strategies.
- Open Access
- 9 October 2024
- Published by MDPI AG in Preprints.org
Definitive Diagnosis of Pleural Mesothelioma by Pleural Effusion Cytology: The MesoCyto Study
Objective: We evaluated the possibility of diagnosing pleural mesothelioma (PM) through pleural effusion cytology in a multicentric prospective clinical trial (MesoCyto study). Methods: We included patients with pleural effusion and suspected PM scheduled for thoracentesis and pleural biopsy. Both pleural effusion cytology including cell block and pleural biopsy were independently performed and compared to assess the diagnostic reliability of pleural effusion cytology. The primary endpoint aimed to demonstrate that the specificity of PM diagnosis by pleural effusion cytology reached 100%. Secondary endpoints included the frequency of adverse events during thoracentesis and pleural biopsy and assessment of diagnostic accuracy of pleural effusion cytology for each histological type. Results: Of the 50 enrolled patients, histological examination confirmed PM in 42 patients; 29 patients met the diagnostic criteria of PM in pleural effusion cytology and received a cytological diagnosis. Of the remaining 21 patients, 13 displayed atypical cells suggestive of PM based on pleural effusion cytology but did not meet the diagnostic criteria, and in 8, atypical cells were not identified and PM diagnostic criteria were not met. Thus, pleural effusion cytology specificity was 100%. The diagnostic concordance rate by pleural effusion cytology for each histological type was 72.2% for epithelioid, 75% for biphasic, and 0% for sarcomatoid. No adverse events were associated with thoracentesis, but the incidence of adverse events during pleural biopsy was 14%. Conclusions: PM can potentially be diagnosed through only pleural effusion cytology including the cell block method using immunohistochemical staining.
- 9 October 2024
- Published by MDPI AG in Preprints.org
Open AccessDefinitive Diagnosis of Pleural Mesothelioma by Pleural Effusion Cytology: The MesoCyto Study
Objective: We evaluated the possibility of diagnosing pleural mesothelioma (PM) through pleural effusion cytology in a multicentric prospective clinical trial (MesoCyto study). Methods: We included patients with pleural effusion and suspected PM scheduled for thoracentesis and pleural biopsy. Both pleural effusion cytology including cell block and pleural biopsy were independently performed and compared to assess the diagnostic reliability of pleural effusion cytology. The primary endpoint aimed to demonstrate that the specificity of PM diagnosis by pleural effusion cytology reached 100%. Secondary endpoints included the frequency of adverse events during thoracentesis and pleural biopsy and assessment of diagnostic accuracy of pleural effusion cytology for each histological type. Results: Of the 50 enrolled patients, histological examination confirmed PM in 42 patients; 29 patients met the diagnostic criteria of PM in pleural effusion cytology and received a cytological diagnosis. Of the remaining 21 patients, 13 displayed atypical cells suggestive of PM based on pleural effusion cytology but did not meet the diagnostic criteria, and in 8, atypical cells were not identified and PM diagnostic criteria were not met. Thus, pleural effusion cytology specificity was 100%. The diagnostic concordance rate by pleural effusion cytology for each histological type was 72.2% for epithelioid, 75% for biphasic, and 0% for sarcomatoid. No adverse events were associated with thoracentesis, but the incidence of adverse events during pleural biopsy was 14%. Conclusions: PM can potentially be diagnosed through only pleural effusion cytology including the cell block method using immunohistochemical staining.
- Open Access
- 26 April 2023
- Published by Elsevier in Lung Cancer
- Vol. 180, 107219
Combination therapy with anti-programmed cell death 1 antibody plus angiokinase inhibitor exerts synergistic antitumor effect against malignant mesothelioma via tumor microenvironment modulation
- 26 April 2023
- Published by Elsevier in Lung Cancer
- Vol. 180, 107219
Open AccessCombination therapy with anti-programmed cell death 1 antibody plus angiokinase inhibitor exerts synergistic antitumor effect against malignant mesothelioma via tumor microenvironment modulation